This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shukeir, N. Articles by Rabbani, S. A. Search for Related Content PubMed PubMed Citation Articles by Shukeir, N. Articles by Rabbani, S. A.

Prostate Secretory Protein PSP-94 Decreases Tumor Growth and Hypercalcemia of Malignancy in a Syngenic in Vivo Model of Prostate Cancer¹

Department of Medicine, Physiology and Oncology, McGill University Health Centre, Montreal, Quebec, H3A 1A1 Canada [N. S., A. A., S. A. R.], and Procyon BioPharma Inc., Montreal, Quebec, Canada [S. K., S. G.]

Prostate cancer is a common malignancy affecting men, which is often associated with skeletal metastases resulting in significant morbidity and mortality. In this hormone-dependent cancer, low levels of a prostate secretory protein of 94 amino acids (PSP-94) are associated with advanced disease stage. In the current study, we have examined the effect of PSP-94 on prostate cancer growth and experimental metastases to the skeleton. For these studies, MatLyLu rat prostate cancer cells were transfected with full-length cDNA encoding parathyroid hormone-related protein [PTHrP (MatLyLu-PTHrP cells)], which is known to be the major pathogenetic factor for malignancy-associated hypercalcemia. MatLyLu-PTHrP cells were inoculated s.c. into the right flank or via intracardiac route into the left ventricle of syngeneic male Copenhagen rats. Intracardiac inoculation of MatLyLu cells routinely results in the development of tumors in the lumbar vertebrae, resulting in hind-limb paralysis. Animals were infused with different doses of PSP-94 (0.1, 1.0, and 10.0 µg/kg/day) starting on the day of tumor cell inoculation. Time of hind-limb paralysis and tumor volume were determined, and comparison was made between PSP-94-treated animals and control animals receiving vehicle alone. At the end of the study, animals were sacrificed, and plasma calcium, plasma PTHrP, and tumor PTHrP levels were determined. Whereas the highest dose of PSP-94 caused a modest but statistically significant delay in the development of hind-limb paralysis, a marked dose-dependent decrease in primary tumor volume was seen in experimental animals receiving PSP-94 due to its ability to promote tumor cell apoptosis. Furthermore, whereas control animals routinely developed hypercalcemia due to PTHrP production, treatment with PSP-94 led to a near normalization of plasma calcium and a marked reduction in PTHrP production as determined by radioimmunoassay and immunohistochemistry. Collectively, these results demonstrate the ability of PSP-94 to be an effective treatment modality for prostate cancer, where decrease in plasma PTHrP and calcium levels can serve as useful biochemical markers for monitoring the efficacy of this novel antitumor agent.

This article has been cited by other articles:

				C. Valtonen-Andre, C. Savblom, P. Fernlund, H. Lilja, A. Giwercman, and A. Lundwall Beta-Microseminoprotein in Serum Correlates With the Levels in Seminal Plasma of Young, Healthy Males J Androl, May 1, 2008; 29(3): 330 - 337. [Abstract] [Full Text] [PDF]

				A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al. Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy Clin. Cancer Res., July 15, 2007; 13(14): 4130 - 4138. [Abstract] [Full Text] [PDF]

				H. Jallal, M.-L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo Cancer Res., February 15, 2007; 67(4): 1580 - 1588. [Abstract] [Full Text] [PDF]

				J. R. Reeves, H. Dulude, C. Panchal, L. Daigneault, and D. M. Ramnani Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin. Cancer Res., October 15, 2006; 12(20): 6018 - 6022. [Abstract] [Full Text] [PDF]

				H. Jiang, K. M. Whitworth, N. J. Bivens, J. E. Ries, R. J. Woods, L. J. Forrester, G. K. Springer, N. Mathialagan, C. Agca, R. S. Prather, et al. Large-Scale Generation and Analysis of Expressed Sequence Tags from Porcine Ovary Biol Reprod, December 1, 2004; 71(6): 1991 - 2002. [Abstract] [Full Text] [PDF]

				N. Shukeir, A. Arakelian, G. Chen, S. Garde, M. Ruiz, C. Panchal, and S. A. Rabbani A Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein Can Reduce Tumor Growth, Experimental Skeletal Metastases, and Malignancy-Associated Hypercalcemia Cancer Res., August 1, 2004; 64(15): 5370 - 5377. [Abstract] [Full Text] [PDF]